BOBCAPS ELIXIR Pharmaceuticals and Healthcare Investment Banking Newsletter Inaugural Edition April – September 2018 BOB CAPITAL MARKETS LTD. A wholly owned subsidiary of Bank of Baroda President’s Note Inside this Edition Dear Reader, 3 Company News It gives me immense pleasure to share the inaugural edition of BOBCAPS ELIXIR, Investment Banking Newsletter covering Pharmaceuticals and Healthcare sectors. Our endeavour is to 6 Industry News publish ELIXIR as a quarterly newsletter covering the industry deal dynamics, trends and events that has shaped the industry in recent times. 7 Key Transactions We have covered the following key subsectors – Pharmaceuticals, Biotechnology & Life Sciences, Healthcare & Diagnostics and Medical Devices & Consumables. 8 Select Deals – Case Study We hope you find this newsletter interesting and we look forward to receiving your feedback to help us improvise on our future editions. Public Market Data 10 Please get in touch with us:
[email protected] Warm Regards, 13 Team Avdhoot Deshpande President, Investment Banking – Equity Company News Product & Regulatory (1/2) Product Launch Glenmark launches Akynzeo in India under licensing pact with Helsinn Glenmark receives US FDA approval for generic Vagifem 10 mcg Glenmark Pharmaceuticals launched Akynzeo, a drug used for prevention of Glenmark Pharmaceuticals Inc, USA (Glenmark) has announced that USFDA has chemotherapy-induced nausea and vomiting, in India and Nepal under an granted final approval for Estradiol Vaginal Inserts USP, 10 mcg, the generic version exclusive licensing pact with Swiss pharma group Helsinn. Akynzeo is an oral fixed of Vagifem, 10 mcg, of Novo Nordisk which is used for providing relief from combination of netupitant (300 mg) and palonosetron (0.5 mg).